Medical Advocates
HCV Infection/Disease
  Investigational Drugs  
General Reports
 Alisporivir
Cannabinoids
Anti-tumor Necrosis Factor-alpha
HEP1
 Levovirin
Resiquimod
Telaprevir
Thymosin alpha1
 Viramidine
 VX-950



 




 
HCV Main Page Main New/Newsworthy HCV Drugs Home Page      

Last Update:  February 06, 2010
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

      Conference Reports, Abstracts, and Posters
 

  CONFERENCE PRESENTATION
 Future Therapy of Hepatitis C
McHutchison JG
 [NIH Consensus Development Conference on  Management of Hepatitis C: 2002]
 Report
Alisporivir
 
      Journal Papers, Abstracts, and Commentaries
 
  Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin,
for the treatment of HCV infection.
 Watashi K.
Curr Opin Investig Drugs. 2010 Feb;11(2):213-24.
 Abstract
Anti-tumor Necrosis Factor-alpha
 
      Journal Papers, Abstracts, and Commentaries
 
  Etanercept treatment for three months is safe in patients with rheumatological
manifestations associated with hepatitis C virus.
 Marotte H, Fontanges E, Bailly F, et al   
Rheumatology (Oxford). 2006 May 23;
 Abstract
Cannabinoids
 
      Journal Papers, Abstracts, and Commentaries
 
  Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye
 Friedman SL.
J Hepatol. 2006 Oct 30;
 Abstract
HEP1
 

     Journal Papers, Abstracts, and Commentaries

  Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected
patients.
Salamov G, Holms R, Bessler WG, Ataullakhanov R.
Arzneimittelforschung. 2007;57(7):497-504.
 Abstract
Levovirin
 
      Journal Papers, Abstracts, and Commentaries
 
  Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives
of ribavirin.
 Watson J.
Curr Opin Investig Drugs 2002 May;3(5):680-3  
Abstract
Resiquimod
 
      Journal Papers, Abstracts, and Commentaries
 
  Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled,
double-blind phase IIa studies
 Pockros PJ, Guyader D, Patton H, Tong MJ, et al
J Hepatol. 2007 May 4;
Abstract
Telaprevir
 
   Journal Papers, Abstracts, and Commentaries
 
  The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
Gentile I, Carleo MA, Borgia F, et al
Expert Opin Investig Drugs. 2010 Jan;19(1):151-9.
 Abstract
 
Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and t
elaprevir (VX 950) in human plasma by LC-MS/MS.
Farnik H, El-Duweik J, Welsch C,
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4001
 Abstract
 
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy
with the NS3-4A protease inhibitor telaprevir.
Suzuki F, Suzuki Y, Akuta N, et al
Clin Virol. 2009 Oct 24.
 Abstract
 
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C
virus-infected patients.
Susser S, Welsch C, Wang Y, et al
Hepatology. 2009 Dec;50(6):1709-18.
 Abstract
 
Telaprevir: hope on the horizon, getting closer.
Weisberg IS, Jacobson IM.
Clin Liver Dis. 2009 Aug;13(3):441-52
 Abstract
 
Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment
with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.
Suzuki F, Akuta N, Suzuki Y, et al
Hepatol Res. 2009 Nov;39(11):1056-63
 Abstract

FULL=TEXT ARTICLE
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
 Hézode C, Forestier N, Dusheiko G, et al
 N Engl J Med. 2009 Apr 30;360(18):1839-50
 Paper

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
 McHutchison JG, Everson GT, Gordon SC, et al
 N Engl J Med. 2009 Apr 30;360(18):1827-38
 Abstract
 
Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.
 Gentile I, Viola C, Borgia F, Castaldo G, Borgia G.
 Curr Med Chem. 2009;16(9):1115-21.
 Abstract

 

 

Thymosin alpha1
 
      Journal Papers, Abstracts, and Commentaries
 
  Thymosin alpha1
 Billich A.
Curr Opin Investig Drugs 2002 May;3(5):698-707
 Abstract   
VX-950
 
      Journal Papers, Abstracts, and Commentaries
 
  Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved
derivatives of ribavirin.
 Watson J.
 Curr Opin Investig Drugs 2002 May;3(5):680-3  
Abstract
Viramidine
 
      Journal Papers, Abstracts, and Commentaries
 
 
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve
patients with chronic hepatitis C: ViSER1 results.
Benhamou Y, Afdhal NH, Nelson DR, et al
 Hepatology. 2009 May 11
 Abstract

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib,
Placebo-Controlled, Randomized Study.
 Reesink HW, Zeuzem S, Weegink CJ, et al
Gastroenterology. 2006 Oct;131(4):997-1002.
 Abstract

HCV Main Page Main New/Newsworthy HCV Drugs Home Page      

HCV Investigational Drugs